Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease

Licette C. Y. Liu, Elise Schutte, Ron T. Gansevoort, Peter van der Meer, Adriaan A. Voors*

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

42 Citaten (Scopus)

Samenvatting

Introduction: The mineralocorticoid receptor antagonists (MRAs) spironolactone and eplerenone reduce the risk of hospitalizations and mortality in patients with heart failure (HF) with reduced ejection fraction (HFrEF), and attenuate progression of diabetic kidney disease. However, their use is limited by the fear of inducing hyperkalennia, especially in patients with renal dysfunction. Finerenone is a novel nonsteroidal MRA, with higher selectivity toward the mineralocorticoid receptor (MR) compared to spironolactone and stronger MR-binding affinity than eplerenone.

Areas covered: This paper discusses the chemistry, pharmacokinetics, clinical efficacy and safety of finerenone.

Expert opinion: The selectivity and greater binding affinity of finerenone to the MR may reduce the risk of hyperkalemia and renal dysfunction and thereby overcome the reluctance to start and uptitrate MRAs in patients with HF and diabetic kidney disease. Studies conducted in patients with HFrEF and moderate chronic kidney disease and diabetic kidney disease, showed promising results. Phase Ill trials will have to show whether finerenone might become the third-generation MRA for the treatment of HF and diabetic kidney disease.

Originele taal-2English
Pagina's (van-tot)1123-1135
Aantal pagina's13
TijdschriftExpert opinion on investigational drugs
Volume24
Nummer van het tijdschrift8
DOI's
StatusPublished - aug-2015

Citeer dit